این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Heart Journal، جلد ۲۶، شماره ۲، صفحات ۳۹-۴۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی The Efficacy and Safety of Ticagrelor Compared With Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction Scheduled for a Pharmaco-Invasive Reperfusion Strategy
چکیده انگلیسی مقاله Background: ST-segment elevation myocardial infarction (STEMI) is a critical component of acute coronary syndrome and is often managed with a pharmaco-invasive strategy when primary percutaneous coronary intervention (pPCI) is not immediately available. Although ticagrelor has demonstrated superior outcomes in pPCI settings, its efficacy and safety compared with clopidogrel in a pharmaco-invasive approach remain less studied. This study aimed to evaluate the safety and efficacy of ticagrelor compared with clopidogrel in STEMI patients undergoing reperfusion with a pharmaco-invasive strategy.   Methods: This randomized controlled trial was conducted among 170 STEMI patients treated with fibrinolytic therapy and scheduled for a pharmaco-invasive strategy. Patients were randomized to receive either ticagrelor (the switch group) or clopidogrel (the no-switch group) in addition to standard therapy. The primary outcomes were major bleeding (safety) and a composite of death, reinfarction, or stroke (efficacy) within 6 months.   Results: The study found no significant differences in in-hospital outcomes, including resuscitated cardiac arrest, shock, and major bleeding between the groups. At 6 months, the composite efficacy endpoint occurred in 1.2% of the ticagrelor group compared with 4.7% in the clopidogrel group (P = 0.368). Kaplan-Meier analysis revealed a divergence in event rates beginning in the fifth month, with the ticagrelor group exhibiting a slightly higher event rate by the sixth month (10% vs 9.8%).   Conclusions: In STEMI patients treated with a pharmaco-invasive strategy, ticagrelor and clopidogrel demonstrated similar safety profiles. Although the ticagrelor group exhibited a lower incidence of the composite efficacy endpoint, this difference was not statistically significant. (Iranian Heart Journal 2025; 26(2): 39-48)
کلیدواژه‌های انگلیسی مقاله STEMI,Pharmaco-invasive strategy,Ticagrelor,Clopidogrel,randomized controlled trial
نویسندگان مقاله Ahmed Mahmoud Bendary |
Cardiovascular Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt.

Osama Sanad Arafa |
Cardiovascular Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt.

Zainab Gomaa Gamal Awad |
New Cairo Specialized Hospital, Cairo, Egypt.

Yasser Hosny Abd El Rahman |
Cardiovascular Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt.

نشانی اینترنتی https://journal.iha.org.ir/article_217910_0529b1c568cd1184c1892eb6f9fe100c.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات